<?xml version="1.0" encoding="UTF-8"?>
<ref id="B79-ijms-21-03544">
 <label>79.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Luna</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Alping</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Burman</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Fink</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Fogdell-Hahn</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Gunnarsson</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Hillert</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Langer-Gould</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Lycke</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Nilsson</surname>
    <given-names>P.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Infection Risks Among Patients with Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies</article-title>
  <source>JAMA Neurol.</source>
  <year>2019</year>
  <pub-id pub-id-type="doi">10.1001/jamaneurol.2019.3365</pub-id>
 </element-citation>
</ref>
